99 active not recruiting. 99 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 99 | Active not recruiting 99 |
| Phase 2 | 10 | Active not recruiting 10 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors BGB-16673, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | BeOne Medicines | 153 | 2025-05-29 | 2026-08-24 |
| PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL PD-1 Inhibitors - Acute T Lymphoblastic Leukemia (T-ALL) | Phase 3 | Active not recruiting | Fujian Medical University Union Hospital | 40 | 2025-05-01 | 2026-04-21 |
| A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma SHR-A1912 Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 282 | 2025-04-24 | 2026-09-25 |
| Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa Efanesoctocog alfa - Haemophilia A (Moderate or Severe) | Phase 3 | Active not recruiting | Swedish Orphan Biovitrum | 89 | 2025-03-06 | 2026-10-19 |
| A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Epcoritamab, Rituximab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Genmab | 379 | 2024-08-13 | 2026-04-08 |
| SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations QTORIN 3.9% Rapamycin Anhydrous Gel - Microcystic Lymphatic Malformation | Phase 3 | Active not recruiting | Palvella Therapeutics, Inc. | 51 | 2024-07-31 | 2026-03-27 |
| Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma Golcadomide, Placebo, Rituximab - Large B-cell Lymphoma | Phase 3 | Active not recruiting | Celgene | 850 | 2024-06-19 | 2026-07-06 |
| Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 Mosunetuzumab, Lenalidomide, Rituximab - Follicular Lymphoma | Phase 3 | Active not recruiting | The Lymphoma Academic Research Organisation | 790 | 2024-06-07 | 2026-09-25 |
| Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Xanamem, Placebo - Dementia Moderate, Dementia, Mild | Phase 2 / Phase 3 | Active not recruiting | Actinogen Medical | 247 | 2024-04-12 | 2026-10-21 |
| A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Odronextamab, Ifosfamide, Carboplatin - B-Cell Non-Hodgkin Lymphoma (B-NHL) | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 216 | 2024-02-15 | 2026-05-11 |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma Epcoritamab, Prednisone, Rituximab - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Genmab | 1095 | 2024-02-05 | 2026-08-04 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis Baricitinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 150 | 2023-12-01 | 2024-08-23 |
| A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 733 | 2023-11-14 | 2026-02-06 |
| Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) Sonrotoclax, Zanubrutinib, Venetoclax - CLL | Phase 3 | Active not recruiting | BeOne Medicines | 652 | 2023-11-11 | 2026-10-14 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 1057 | 2023-10-25 | 2026-04-23 |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Belinostat Injection, Pralatrexate Injection, CHOP - Peripheral T Cell Lymphoma | Phase 3 | Active not recruiting | Acrotech Biopharma Inc. | 504 | 2023-10-04 | 2026-10-15 |
| A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 109 | 2023-10-02 | 2026-04-17 |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Biospecimen Collection, Calaspargase Pegol, Levocarnitine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | Children's Oncology Group | 440 | 2023-08-24 | 2026-08-21 |
| Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis STOP arm - Sarcoidosis | Phase 3 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 32 | 2023-03-23 | 2026-04-24 |
| A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) Nemtabrutinib, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2023-03-16 | 2026-03-16 |
Showing 20 of 99. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (21) · Lymphoma (17) · Lymphoma, Follicular (16) · Lymphoma, Non-Hodgkin (16) · Lymphoma, Large B-Cell, Diffuse (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Hodgkin Disease (6) · Leukemia, Biphenotypic, Acute (6) · Lymphoma, B-Cell (6) · Recurrence (6) · Burkitt Lymphoma (5) · Lymphoma, Mantle-Cell (5) · Neoplasms (5) · Hematologic Diseases (4) · Leukemia (4)
Hemic and Lymphatic Diseases (99) · Immune System Diseases (94) · Lymphoproliferative Disorders (93) · Neoplasms by Histologic Type (90) · Immunoproliferative Disorders (89) · Neoplasms (86) · Lymphoma (46) · Hematologic Diseases (40) · Leukemia, Lymphoid (38) · Leukemia (36) · Lymphoma, Non-Hodgkin (36) · Pathological Conditions, Signs and Symptoms (31) · Pathologic Processes (29) · Disease Attributes (27)
Rituximab (42) · Cyclophosphamide (26) · Vincristine (23) · Doxorubicin (22) · Prednisone (22) · Lenalidomide (14) · Cytarabine (13) · obinutuzumab (13) · Bendamustine Hydrochloride (12) · Etoposide (11) · Methotrexate (11) · venetoclax (11) · Dexamethasone (10) · ibrutinib (10) · pegaspargase (10)
National Cancer Institute (NCI) (11) · Acerta Pharma BV (6) · Genmab (6) · BeOne Medicines (4) · Children's Oncology Group (4) · Loxo Oncology, Inc. (4) · AstraZeneca (3) · Children's Cancer Group, China (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Hoffmann-La Roche (3) · Incyte Corporation (3) · Memorial Sloan Kettering Cancer Center (3) · Assistance Publique - Hôpitaux de Paris (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Fondazione Italiana Linfomi - ETS (2)
United States (69) · Australia (43) · Canada (43) · France (43) · Italy (42) · Poland (42) · Spain (42) · China (35) · United Kingdom (34) · Belgium (32) · Germany (32) · Taiwan (32) · Israel (31) · South Korea (30) · Czechia (28)
Christophe Ferme (2) · H. Eghbali, MD (2) · Jennifer A Woyach (2) · Tait D Shanafelt (2) · Alex F Herrera (1) · Andrea Biondi (1) · Anna Raciborska (1)
PMID 38598745, PMID 39563886, PMID 42329537, PMID 10552938, PMID 10627444, PMID 15486066, PMID 15936157, PMID 16421426, PMID 17003366, PMID 17097834, PMID 17989384, PMID 19139435, PMID 19433688, PMID 19828373, PMID 20516455, PMID 20679620, PMID 22940833, PMID 23389497, PMID 24344215, PMID 25901426, PMID 26887549, PMID 28273702, PMID 28601705, PMID 28787259, PMID 29229324, PMID 30501481, PMID 31112475, PMID 31365801, PMID 31875923, PMID 31935289, PMID 32305093, PMID 32459600, PMID 32589970, PMID 32661576, PMID 32730187, PMID 32985902, PMID 32987765, PMID 33054121, PMID 33164993, PMID 33288485, PMID 33439748, PMID 33651090, PMID 33709202, PMID 33796237, PMID 33844429, PMID 34274940, PMID 34310172, PMID 34388007, PMID 34398557, PMID 34534514
2023 (19), 2019 (5), U10CA180886 (5), U10CA180820 (4), 2017 (3), U10CA180821 (3), 2014 (2), 2015 (2), U10CA021115 (2), U10CA098543 (2), U10CA180888 (2), U24CA196172 (2), UG1CA189955 (2), 2018 (1), K23CA178183 (1)